Unity Biotechnology, Inc.

As of March 15, 2023, Unity Biotechnology, Inc. has been downgraded to "does not qualify" due to being overvalued with a negative price-to-book value of -11.72 and an EV to EBIT ratio of 0.04, while its stock has underperformed the S&P 500 with a year-to-date return of -23.19%.

As of June 11, 2025, the market trend is mildly bearish, influenced by bearish weekly indicators and mixed signals from monthly trends, suggesting caution.

As of March 2022, the management team of Unity Biotechnology, Inc. includes Chairman Keith Leonard, CEO Anirvan Ghosh, President Nathaniel David, and several directors with diverse expertise, including Mary Campbell, Robert Nelsen, Gilmore O'Neill, Luis Visoso, and independent director Paul Berns.

Unity Biotechnology, Inc. is a clinical stage biotechnology company focused on developing therapeutics for aging-related diseases. It has a market cap of $13.36 million and reported a net profit loss of $7 million as of March 2025.

As of Jun 18, Unity Biotechnology, Inc. has a market capitalization of 13.36 million and reported net sales of 0.00 million with a net profit of -27.50 million over the last four quarters. The balance sheet shows shareholder's funds of 6.49 million and total assets of 40.41 million.